Advertisement

Referrals

  • Michael Smith
Chapter

Introduction

This chapter will discuss both the process of referral in long-term care settings and the kinds of referrals psychologists typically get in these settings. The emphasis will be on nursing homes, but mention will be made of assisted-living facilities, retirement residences and other settings, especially when there appear to be differences between these settings and nursing homes.

The Referral Process

The process of referral is complex for at least two reasons. First, different insurance carriers have different requirements and procedures for referral; second, nursing homes and, to a lesser extent, other long-term care settings are heavily regulated by state and federal law.

Insurance

The primary insurer for most residents of long-term care is Medicare, which includes coverage for psychological services under Part B. Depending on the local carrier, there is some variability in how Medicare Part B is administered across the country. Carriers are private insurance companies...

Keywords

Chronic Obstructive Pulmonary Disease Behavior Problem Nursing Home Medical Illness Cognitive Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Allen, J. E. (2000). Nursing home federal requirements and guidelines to surveyors. (4th ed.)Springer.New York:Google Scholar
  2. Briesacher, B. A., Limcangco, M. R., Simoni-Wastila, L., et al. (2005). The quality of antipsychotic drug prescribing in nursing homes. Archives of Internal Medicine, 165, 1280–1285.PubMedCrossRefGoogle Scholar
  3. Glenmullen, J. (2000). Prozac backlash: Overcoming the dangers of Prozac, Zoloft, Paxil, and other antidepressants with safe effective alternatives. Simon and Schuster.New York:Google Scholar
  4. U.S. Food and Drug Administration. (2005). FDA public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Retrieved May 3, 2005, from http://www.fda.gov/cder/drug/advisory/antipsychotics.htm
  5. Valenstein, E. S. (1998). Blaming the brain: The truth about drugs and mental health. The Free Press.New York:Google Scholar
  6. Wang, P. S., Schneeweiss, S., Avorn, J., et al. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. The New England Journal of Medicine, 353, 2335–2341.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Michael Smith

There are no affiliations available

Personalised recommendations